Literature DB >> 15215254

APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.

Timothy M Alce1, Waldemar Popik.   

Abstract

APOBEC3G belongs to the family of cellular cytidine deaminase-editing enzymes with a potent antiretroviral activity, which is counteracted by the Vif protein expressed by lentiviruses. Antiretroviral activity of APOBEC3G requires its packaging into assembling virions, presumably to ensure its close association with nascent retroviral cDNA. Here, we demonstrate that APOBEC3G is encapsidated through a direct interaction with the HIV-1 Gag polyprotein which likely takes place on the membranes of the multivesicular bodies (MVB)/late endosomal compartments. This interaction is mediated by the Gag nucleocapsid protein NC, and the N-terminal part of NC is most critical for this interaction. Binding to the NC domain would ensure that APOBEC3G will be concentrated in the viral core of mature HIV-1, in close proximity to the reverse transcription complex.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15215254     DOI: 10.1074/jbc.C400235200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  142 in total

1.  Association of potent human antiviral cytidine deaminases with 7SL RNA and viral RNP in HIV-1 virions.

Authors:  Wenyan Zhang; Juan Du; Kevin Yu; Tao Wang; Xiong Yong; Xiao-Fang Yu
Journal:  J Virol       Date:  2010-10-06       Impact factor: 5.103

2.  The localization of APOBEC3H variants in HIV-1 virions determines their antiviral activity.

Authors:  Marcel Ooms; Susan Majdak; Christopher W Seibert; Ariana Harari; Viviana Simon
Journal:  J Virol       Date:  2010-06-02       Impact factor: 5.103

Review 3.  Function of a retrotransposon nucleocapsid protein.

Authors:  Suzanne B Sandmeyer; Kristina A Clemens
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

4.  The cellular antiviral protein APOBEC3G interacts with HIV-1 reverse transcriptase and inhibits its function during viral replication.

Authors:  Xiaoxia Wang; Zhujun Ao; Liyu Chen; Gary Kobinger; Jinyu Peng; Xiaojian Yao
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

5.  Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS.

Authors:  Judd F Hultquist; Reuben S Harris
Journal:  Future Virol       Date:  2009-11-01       Impact factor: 1.831

6.  Characterization of anti-HIV activity mediated by R88-APOBEC3G mutant fusion proteins in CD4+ T cells, peripheral blood mononuclear cells, and macrophages.

Authors:  Zhujun Ao; Xiaoxia Wang; Alexander Bello; Kallesh Danappa Jayappa; Zhe Yu; Keith Fowke; Xinying He; Xi Chen; Junhua Li; Gary Kobinger; Xiaojian Yao
Journal:  Hum Gene Ther       Date:  2011-03-18       Impact factor: 5.695

7.  A multi-scale mathematical modeling framework to investigate anti-viral therapeutic opportunities in targeting HIV-1 accessory proteins.

Authors:  Gajendra W Suryawanshi; Alexander Hoffmann
Journal:  J Theor Biol       Date:  2015-09-16       Impact factor: 2.691

8.  CBFβ enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G.

Authors:  Eri Miyagi; Sandra Kao; Venkat Yedavalli; Klaus Strebel
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

9.  Single-stranded RNA facilitates nucleocapsid: APOBEC3G complex formation.

Authors:  Hal P Bogerd; Bryan R Cullen
Journal:  RNA       Date:  2008-05-02       Impact factor: 4.942

10.  Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.

Authors:  Hal P Bogerd; Rebecca L Tallmadge; J Lindsay Oaks; Susan Carpenter; Bryan R Cullen
Journal:  J Virol       Date:  2008-09-25       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.